A double-blind comparison of fluvoxamine, desipramine and placebo in outpatients with depression
Progress in Neuro-Psychopharmacology and Biological PsychiatryPublished 1 January 1990
Deborah A. Roth, Jeffrey A. Mattes, Kathy H. Sheehan, David V. Sheehan
Citations43
SJR quartileQ1
SJR score1.77
SNIP1.37
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
Although overall drug effects were relatively weak, there were trends suggesting separation of both active drugs from placebo at week six, and both drugs were well tolerated.
Abstract
1. The efficacy of fluvoxamine is compared to that of desipramine in a multicenter double blind placebo controlled six-week flexible dose trial of 90 outpatients with major depressive disorder. 2. Although overall drug effects were relatively weak, there were trends suggesting separation of both active drugs from placebo at week six. Both drugs were well tolerated. 3. Studies of major depression ought to be designed to last 8-10 weeks in order to demonstrate placebo active drug differences and the stability of such a difference should it occur in the first six weeks.
Keywords
PsychologyMedicine
Archives of General PsychiatryAn Inventory for Measuring Depression
38,163 Citations1961Aaron T. Beck
The difficulties inherent in obtaining consistent and adequate diagnoses for the purposes of research and therapy have been pointed out and a wide variety of psychiatric rating scales have been developed.
The British Journal of PsychiatryA New Depression Scale Designed to be Sensitive to Change
13,927 Citations1979Stuart Montgomery, Marie Åsberg
The construction of a depression rating scale designed to be particularly sensitive to treatment effects is described, and its capacity to differentiate between responders and non-responders to antidepressant treatment was better than the HRS, indicating greater sensitivity to change.
British Journal of Social and Clinical PsychologyDevelopment of a Rating Scale for Primary Depressive Illness
8,470 Citations1967Max Hamilton
This is an account of further work on a rating scale for depressive states, including a detailed discussion on the general problems of comparing successive samples from a ‘population’, the meaning of factor scores, and the other results obtained.
Systems Research and Behavioral ScienceThe Hopkins Symptom Checklist (HSCL): A self-report symptom inventory
4,656 Citations1974Leonard R. Derogatis, Ronald S. Lipman +3 more
The historical evolution, development, rationale and validation of the Hopkins Symptom Checklist is described, a self-report symptom inventory comprised of 58 items which are representative of the symptom configurations commonly observed among outpatients.
Science"Serotonin Depression"—A Biochemical Subgroup Within the Affective Disorders?
679 Citations1976Marie Åsberg, Peter Thorén +3 more
There was a significant correlation between the concnetration of 5-HIAA and severity of depression in the lower, but not in the upper, mode, which suggests the existence of a biochemical subgroup of depressive disorder, characterized by a disturbance of serotonin turnover.
DrugsFluvoxamine
496 Citations1986Paul Benfield, Alan Ward
In patients with depressive illness, fluvoxamine offers a suitable alternative to tricyclic antidepressants and may be especially valuable in patients with concomitant cardiovascular disease, and those unresponsive to or unable to tolerate tricyClic antidepressants.
ScienceTritiated Imipramine Binding Sites Are Decreased in the Frontal Cortex of Suicides
471 Citations1982Michael Stanley, Joanne Virgilio +1 more
Binding characteristics of tritiated imipramine were determined in the frontal cortex of suicides and well-matched controls and were consistent with reports of decreased tritiations in the platelets of patients diagnosed as having a major affective disorder.
ScienceTritiated Imipramine Binding Sites Are Decreased in Platelets of Untreated Depressed Patients
439 Citations1980Michael S. Briley, Salomón Z. Langer +3 more
Results suggest that binding of tritiated imipramine in human platelets may represent a biochemical index of depression, possibly reflecting similar changes in the brain.
The British Journal of Psychiatry5-Hydroxytryptamine in the Hind-Brain of Depressive Suicides
430 Citations1967David M. Shaw, F. E. Camps +1 more
The knowledge that loss of amines may be associated with depression, and that their replenishment in the brain may induce recovery, immediately leads to the question as to which of the biogenic amines is responsible for the affective changes.
The LancetNORADRENALINE, 5-HYDROXYTRYPTAMINE, AND 5-HYDROXYINDOLEACETIC ACID IN HINDBRAINS OF SUICIDAL PATIENTS
303 Citations1968H.R. Bourne
5-H.A.T., noradrenaline, and 5-hydroxyindoleacetic acid levels were not significantly different, but 5- H.I.A.'s levels was significantly lower in the hindbrains of the suicides.
Archives of General PsychiatrySerotonin Uptake in Blood Platelets of Psychiatric Patients
234 Citations1981Herbert Y. Meltzer
Platelet serotonin (5-HT) uptake was determined in 72 newly admitted, unmedicated psychiatric patients and there was a trend for the increase in Km in the nortriptyline-treated patients to correlate with clinical improvement.
Archives of General PsychiatryDuration of Antidepressant Drug Treatment
231 Citations1984Frederic M. Quitkin
It was predicted, and found, that a significant proportion of patients who showed no clear-cut response at four weeks would show much improvement at six weeks in drug but not placebo conditions, and that this would be the case for patients receiving drug and patients receiving placebo.
British Journal of PharmacologyFLUVOXAMINE, A SPECIFIC 5‐HYDROXYTRYPTAMINE UPTAKE INHIBITOR
180 Citations1977V. Claassen, Julia Davies +2 more
Fluvoxamine has been characterized as a potential anti‐depressant drug with almost exclusively 5‐hydroxytryptamine (5‐HT) uptake inhibiting properties.
The British Journal of PsychiatryPhenelzine and Amitriptyline: Effects on Symptoms of Neurotic Depression
99 Citations1982Peter Rowan, Eugene S. Paykel +1 more
The findings indicate that MAO inhibitors and tricyclic antidepressants have more closely similar clinical effects than has been thought and that either may be a useful treatment for patients who are often considered to respond poorly to antidepressant drug treatment.
Comprehensive PsychiatryCentral monoamine metabolism in depressions. I. Serotonin and related compounds
98 Citations1980H. M. van Praag
Research into the possible significance of disorders of the central 5-HT metabolism in the pathogenesis of recurrent depressions is reviewed, with the tentative conclusion that such metabolic disorders are indeed involved in a certain subcategory of vital depressions and play a (possible predisposing) role in the Pathogenesis of these depressions.
British Journal of Clinical PharmacologyA double‐blind placebo‐controlled study of fluvoxamine and imipramine in out‐patients with primary depression.
80 Citations1983T. Itil, Shrivastava Rk +3 more
It is postulated on the basis of quantitative pharmaco-EEG findings, that the slight superiority of imipramine over fluvoxamine was due to underdosing of the latter.
British Journal of Clinical PharmacologyCardiac effects of antidepressant drugs. A comparison of the tricyclic antidepressants and fluvoxamine.
71 Citations1983J. P. Roos
The cardiovascular effects of the tricyclic antidepressants are reviewed and compared with those of fluvoxamine, a new 5-hydroxytryptamine (5-HT) re-uptake inhibitor.
European Journal of PharmacologyAntagonism by antidepressants of serotonin S1 and S2 receptors of normal human brain in vitro
67 Citations1986Theodore J. Wander, Albert N. Nelson +2 more
Using radioligand binding techniques and human frontal cortex, equilibrium dissociation constants (KDs) of 25 antidepressants at the serotonin S1 (probably the S1A subtype) and serotonin S2 receptors were determined using [3H]WB4101 and [3h]ketanserin, respectively.
British Journal of Clinical PharmacologyA double‐blind controlled clinical trial comparing fluvoxamine with imipramine.
67 Citations1983JD Guelfi, J.F. Dreyfus +1 more
It is concluded that fluvoxamine seems to have the same general antidepressant efficacy as imipramine, and was not associated with any safety problems and was generally well tolerated.
PubMedA double-blind placebo-controlled study of fluvoxamine and imipramine in depression.
65 Citations1985Dominguez Ra, Goldstein Bj +2 more
British Journal of Clinical PharmacologyPharmaco‐EEG profiles of antidepressants. Pharmacodynamic studies with fluvoxamine.
62 Citations1983B. Saletu, J Grünberger +1 more
Comparisons with the reference drug revealed a significant superiority of fluvoxamine regarding concentration, psychomotor activity, tapping, reaction time, mood and affectivity and the relationships between pharmacodynamics and pharmacokinetics may be determined.
PubMedTreatment of major affective disorder with fluvoxamine.
60 Citations1987Lapierre Yd, Michael W. Browne +6 more
A placebo-controlled, double-blind study of 63 inpatients with major affective disorder was performed and results indicate that fluvoxamine and imipramine are superior to placebo and demonstrate a trend toward superiority of flu voxamine over imipramsine.
British Journal of Clinical PharmacologyClinical trials of fluvoxamine vs chlorimipramine with single and three times daily dosing.
59 Citations1983JE de Wilde, C. Mertens +1 more
Fluvoxamine, given in a single daily dose of 150-250 mg, provides antidepressant efficacy similar to chlorimipramine at similar dosages, and may be expected to produce less anticholinergic effects and have less influence on blood pressure than chlorimIPramine.
European Journal of Drug Metabolism and PharmacokineticsFluvoxamine maleate; Disposition in man
53 Citations1983H. de Bree, J. B. van der Schoot +1 more
It is concluded that orally administered fluvoxamine is completely absorbed, and the plasma level decreased according to first-order kinetics with a half-life of 14.9 hours.
Journal of Affective DisordersA double-blind comparison of fluvoxamine, imipramine and placebo in depressed patients
49 Citations1984Kingsley Norton, Lester Sireling +3 more
In a placebo-controlled, double-blind study of 91 out-patient depressives, the anti-depressant effect of fluvoxamine, a selective serotonin uptake inhibitor was compared to that of imipramine, showing both active drugs superior to placebo.
Progress in Neuro-Psychopharmacology and Biological PsychiatryFluvoxamine maleate, a serotonergic antidepressant; A comparison with chlorimipramine
40 Citations1982Bernard S. Coleman, Barbara A. Block
In a population of 98 subjects suffering from a variety of depressive conditions, there was a marked improvement over four weeks in both groups and there were fewer concurrent signs and symptoms in the fluvoxamine group, especially those attributable to anticholinergic activity.
The British Journal of Psychiatry[no title]
32 Citations1968Brian Carroll
What was shown by the comparison between the two treatment eras was that, as a group, patients treated with drugs had a better short-term outcome, and that whereas with earlier somatic treatments, such as deep insulin, the patients who responded favourably were probably those destined for a more benign course of illness.
Drug Development ResearchA double‐blind clinical trial of fluvoxamine and imipramine in patients with primary depression
28 Citations1984William Guy, William H. Wilson +4 more
Fluvoxamine, a new serotonin‐reuptake inhibitor, and imipramine were compared under double‐blind conditions in 36 unipolar and bipolar depressed inpatients, with significant reductions in depressive symptomatology over a 4–6‐wk course of treatment.
International PharmacopsychiatryLong-Term Study of Fluvoxamine:a New Rapid-Acting Antidepressant
27 Citations2017Harry S. Feldmann, Herman C.B. Denber
Progress in Neuro-PsychopharmacologyFluvoxamine (DU-23,000), a new antidepressant. Quantitative pharmaco-electroencephalography and pilot clinical trials
23 Citations1977T. Itil, A. Bhattachyaryya +3 more
“stimulant” type of antidepressant effects of fluvoxamine are predicted, as measured by Computer Analyzed EEG, based on a quantitative pharmaco-EEG study in healthy volunteers and open pilot trials in depressive patients with fluv oxamine.
PubMedDesipramine: an overview.
22 Citations1984Janowsky Ds, Bill Byerley
It is proposed that factors including a long "track record," perceived lack of anticholinergic effects, suggestions of earlier onset of action, and the concept of noradrenergic specificity have contributed to the widespread clinical use of desipramine.
Progress in Neuro-Psychopharmacology and Biological PsychiatryEffects of antidepressants on uptake and receptor systems in the brain
21 Citations1985Ray W. Fuller, Dawn M. Wong
Evidence that adaptive changes in neurotransmitter receptors occur after chronic treatment of laboratory animals with these drugs, and these changes may be important components of the overall mechanism of antidepressant efficacy, is limited.
PubMedA double-blind clinical trial of fluvoxamine and imipramine in patients with primary depression.
21 Citations1984Guy W, Wilson Wh +4 more